Аннотация:Cariprazine is a new piperazine derivative atypical antipsychotic, like aripiprazole and brexpiprazole. It hasbeen approved for treating schizophrenia in many countries and has recently been included on the List of EssentialMedicines in Russia. Unlike most other atypical antipsychotics, it shows high in vivo occupancy of dopamine D2 andD3 receptors at clinically relevant doses. In animal models, cariprazine has demonstrated dopamine D3 receptor-dependent pro-cognitive and anti-anhedonic effects, suggesting its potential for treating negative symptoms. Thisreview summarizes the efficacy of cariprazine in the treatment of negative symptoms of schizophrenia.